Of the 58 cardiovascular patient groups, 41% represent patient interests to drug regulators. They most commonly participate in public hearings and consultations (12%), while 16% seek to influence healthcare policy and legislation.
41% of respondents from Cardiovascular conditions ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Cardiovascular conditions sub-type
58 patient groups across 3 sub-types
interactions
One of several examples is the participation of our patient organisation in the registration process for a medicinal product intended for the treatment of ATTR [Transthyretin] amyloidosis, which is entering the Czech Republic via the so-called third orphan route.
One of several examples is the participation of our patient organization in the registration process for a medicinal product intended for the treatment of ATTR amyloidosis, which is entering the Czech Republic via the so-called third orphan route—patients here comment on the benefits of therapy based on specific case studies.
National cardiovascular patient group, Czech Republic
interactions
AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases.
AISC è in frequente controllo con AIFA, con i decisori nazionali e regionali dell'introduzione e adozione di nuovi farmaci nelle patologie cardiovascolari.
National heart-conditions patient group, Italy
actions & advocacy
We have agreements in place with a number of pharmaceutical companies to provide our patients with preferential pricing.
Tenemos convenios con algunas farmacéuticas para precios preferentes a nuestros pacientes.
National cardiovascular patient group, Mexico
actions & advocacy
Successfully advocating for expanding public funding for medications. Advocating for a national heart health action plan.
Successfully advocating for expanding of public funding for medications. Advocating for a national heart health action plan.
National cardiovascular patient group, New Zealand
The percentages below highlight how the 25 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
6 mentions
2 mentions
2 mentions
1 mention
1 mention
4 mentions
2 mentions
1 mention
1 mention
3 mentions
3 mentions
2 mentions
1 mention
1 mention
actions & advocacy
6 mentions
4 mentions
1 mention
1 mention
4 mentions
2 mentions
1 mention
1 mention
3 mentions
2 mentions
1 mention
2 mentions
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
